l e t t e r s
We conducted a meta-analysis to identify new susceptibility loci for testicular germ cell tumor (TGCT). In the discovery phase, we analyzed 931 affected individuals and 1,975 controls from 3 genome-wide association studies (GWAS). We conducted replication in 6 independent sample sets comprising 3,211 affected individuals and 7,591 controls. In the combined analysis, risk of TGCT was significantly associated with markers at four previously unreported loci: 4q22.2 in HPGDS (perallele odds ratio (OR) = 1.19, 95% confidence interval (CI) = 1.12-1.26; P = 1.11 × 10 −8 ), 7p22.3 in MAD1L1 (OR = 1.21, 95% CI = 1.14-1.29; P = 5.59 × 10 −9 ), 16q22.3 in RFWD3 (OR = 1.26, 95% CI = 1.18-1.34; P = 5.15 × 10 −12 ) and 17q22 (rs9905704: OR = 1.27, 95% CI = 1.18-1.33; P = 4.32 × 10 −13 and rs7221274: OR = 1.20, 95% CI = 1.12-1.28; P = 4.04 × 10 −9 ), a locus that includes TEX14, RAD51C and PPM1E. These new TGCT susceptibility loci contain biologically plausible genes encoding proteins important for male germ cell development, chromosomal segregation and the DNA damage response.
In the United States, TGCT is the most common cancer in young men, with peak incidence among those aged 25 to 34 years. The incidence of TGCT has more than doubled among men of European ancestry in the United States over the past 30 years; similar increases in incidence rates have been observed in other populations of European ancestry [1] [2] [3] . Of note, the incidence of TGCT varies widely between populations and is much higher in individuals of European ancestry than in those of African ancestry 2 . Established risk factors for TGCT include family history of the disease, cryptorchidism, adult height and a prior history of TGCT; several recent studies have also implicated marijuana use [4] [5] [6] [7] . First-degree relatives of affected men have consistently been shown to have greater risk of TGCT (5-to 19-fold higher for the brothers of affected men and 2-to 4-fold higher for the sons of affected men) [8] [9] [10] [11] , the highest for any cancer. Furthermore, the estimated heritability of TGCT is the third highest among all cancers, with genetic effects estimated to account for 25% of susceptibility to TGCT 12 . These observations, coupled with findings in twin studies [13] [14] [15] , support a strong genetic component contributing to susceptibility to TGCT.
Despite the greatly increased relative risk of TGCT in the family members of affected men, candidate gene and linkage approaches have shown little progress in identifying specific genetic risk factors. Initially, two independent GWAS identified allele variation within KITLG at 12q22 as the strongest genetic risk factor for TGCT 16, 17 , with a per-allele OR of greater than 3. Variants at 5p15.33 (TERT; two independent loci), 5q31.3 (SPRY4), 6p21.3 (BAK1), 9p24.3 (DMRT1; two independent loci) and 12p13.1 (ATF7IP) have also been associated with risk of TGCT [16] [17] [18] [19] [20] [21] . The per-allele ORs for the identified l e t t e r s TGCT susceptibility alleles are in large part higher than those identified for other cancers, which may be owing, in part, to the homogeneity of the disease, as all TGCTs are thought to arise from primordial germ cells 22, 23 . Many additional loci are expected to contribute to susceptibility, as has been shown for cancers of lower heritability 24 . Combining multiple GWAS data sets represents a strategy to increase the power to detect additional genetic risk factors that did not reach genome-wide significance in individual studies.
We performed a meta-analysis of the 340 most promising SNPs (after excluding previously reported loci) observed in the adjusted pooled analysis of the combined National Cancer Institute (NCI) scan ( Table 2) . We selected the most significant SNP marker from each of nine loci, plus eight additional markers, for replication. We performed an in silico analysis of these 17 SNPs in GWAS data from the University of Southern California (USC) and the UK Testicular Cancer Collaboration (UKTCC) 18 , which was followed by genotyping in four additional TGCT case-control studies from the Fred Hutchinson Cancer Center (Adult Testicular Lifestyle and Blood Specimen (ATLAS) study), the University of Pennsylvania (Testicular Cancer in Philadelphia Area Counties (TestPAC) study), the Oslo University Hospital-The Radium Hospital, Norway (OUHRH) and the MD Anderson Cancer Center (MDA). Details of each study are included in the Supplementary Note. The combined analysis included 4,142 TGCT cases and 9,566 controls (Supplementary Table 3 ). In the combined meta-analysis, we observed four new loci significantly associated with TGCT (P < 5 × 10 −8 ; Table 1 and Supplementary Table 4) .
The most significantly associated SNP marker at 4q22.2, rs17021463, was located in the intron of the HPGDS gene encoding hematopoietic prostaglandin D synthase (P = 1.11 × 10 −8 ; OR = 1.19, 95% CI = 1.12-1.26) (Fig. 1a and Table 1 ). In mice, Hpgds is expressed in the early embryonic male gonad and seems to regulate nuclear localization of the Sox9 protein 25 . Disruption of Hpgds leads to modification of the phenotype of Apc Min/+ mice 26 . Seventy-one surrogate markers were highly correlated with rs17021463 in HPGDS (r 2 ≥ 0.8, 1000 Genomes Project CEU data (Utah residents of Northern and Western European ancestry); Supplementary Table 5) . Notably, rs35744894 (r 2 = 0.87) alters a DMRT2-binding motif (Supplementary Table 6 ); variation in DMRT1 has been associated with risk of TGCT 19 .
Fifty-three of 71 surrogate markers that were highly correlated with the rs17021463 SNP in HPGDS (r 2 ≥ 0.8, 1000 Genomes Project CEU data; Supplementary Table 5) across a 200-kb window mapped within or near an adjacent gene, SMARCAD1 (encoding SWI/SNFrelated, matrix-associated actin-dependent regulator of chromatin, subfamily a, containing DEAD/H box 1). SMARCAD1 is a chromatin remodeler that restores silenced heterochromatin domains in dividing cells and participates in the DNA damage response 27, 28 . Mice with homozygous mutations in Smarcad1 (Etl1) show developmental defects, including impaired fertility 29 . Surrogate markers included one nonsynonymous substitution, rs7439869, at codon 301 (r 2 = 0.93, 1000 Genomes Project CEU data; c.902T>C; p.Val301Ala). Although the mutation at rs7439869 is predicted by PolyPhen-2 to be tolerated 30 , it changes an OCT4-(encoded by POUF5F1) and SOX4-binding motif (Supplementary Table 6 ). OCT4 is a transcription factor that regulates pluripotency in a number of cell types, including primordial germ cells, and is expressed in TGCTs [31] [32] [33] [34] [35] [36] .
We identified a locus at 7p22.3 harboring the MAD1L1 gene (mitotic arrest deficient like 1), which encodes MAD1. The most significantly associated SNP without study heterogeneity, rs12699477, was located in intron 17 of this gene (P = 5.59 × 10 −9 ; OR = 1.21, 95% CI = 1.14-1.29) (Fig. 1b) . Of note, the risk-conferring allele (C) at rs12699477 is more prevalent in populations of European ancestry (29%) than in those of African ancestry (8%) in 1000 Genomes Project data 37 . MAD1 is a spindle assembly checkpoint protein that delays the onset of anaphase in the mitotic cell cycle until all sister chromatids achieve proper alignment and microtubule attachment, thereby preventing aneuploidy and maintaining genomic stability 38 .
Of the 35 SNPs that were highly correlated with rs12699477 in MAD1L1 (r 2 ≥ 0.7, 1000 Genomes Project CEU data; Supplementary Table 5 ), rs1801368 is a missense variant at codon 558 (c.1673G>A; p.Arg588His) that is located in the region encoding the second leucine-zipper domain of MAD1L1. The p.Arg558His alteration has been reported to be associated with lung cancer risk 39 and may lead to reduced binding of MAD2 to MAD1, resulting in decreased proficiency in enforcing mitotic arrest 40 . We observed additional statistically significant associations with TGCT for neighboring SNPs in the MAD1L1 region, including for rs10275045 (P = 3.78 × 10 −10 ; OR = 1.20, 95% CI = 1.13-1.27) and rs3778991 (P = 6.73 × 10 −10 ; OR = 1.21, 95% CI = 1.14-1.28). However, both showed significant heterogeneity between studies (Supplementary Table 4 ). The r 2 values between our strongest signal at rs12699477 and these markers were 0.66 and 0.50, respectively, in the STEED controls. Conditional analysis showed a marked attenuation of the two significantly associated neighboring SNPs, supporting the idea that there is a single TGCT susceptibility locus across the MAD1L1 gene at 7q22.3 (Supplementary Table 7) .
We observed a significant association with TGCT for rs4888262 at 16q22.3 (P = 5.15 × 10 −12 ; OR = 1.26, 95% CI = 1.18-1.34), which is a synonymous SNP in codon 404 (c.1212G>A; p.Thr404) of the RFWD3 gene (encoding ring finger WD domain 3) ( Fig. 1c and Table 1 ). The RFWD3 protein is an E3 ubiquitin ligase that positively regulates p53 stability by forming an RFWD3-MDM2-p53 complex, thereby protecting p53 from degradation by MDM2-mediated polyubiquitination 41, 42 . Within the linkage disequilibrium (LD) interval were SNPs that mapped to two additional genes, GLG1 (encoding Golgi glycoprotein 1) and MLKL (encoding mixed-lineage kinase domain like), the latter of which has been recently identified as a key mediator of tumor necrosis factor (TNF)-induced necrosis, downstream of receptor-interacting protein kinase 3 (RIP3) 43, 44 (Fig. 1c) . We note that rs3851729, which is highly correlated with rs4888262 (r 2 = 0.77, 1000 Genomes Project CEU data), maps to a highly conserved sequence in the 3′ UTR of GLG1; similarly, rs4072222 (r 2 = 0.87, 1000 Genomes Project CEU data) maps to an intron of MLKL (Supplementary Table 5 ). Both susceptibility variants are cis expression quantitative trait loci (eQTLs) that influence both MLKL and RFWD3 expression in monocytes 45 .
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Each locus harbors biologically plausible candidate genes, implicating several pathways-most notably, spermatogenesis and male germ cell development (HPGDS, SMARCAD1, SEPT4, TEX14, RAD51C, PPM1E and TRIM37), chromosomal segregation (MAD1L1, TEX14 and SKA2) and the DNA damage response (SMARCAD1, RFWD3 and RAD51C). None of the four newly identified loci have previously been implicated in GWAS of other cancers, further supporting the idea that there are distinct pathways and regions implicated in TGCT susceptibility; however, rare mutations in RAD51C have been implicated in ovarian cancer susceptibility 53 . Susceptibility to TGCT is particularly unique in that many of the associated genes affect male germ cell development and differentiation, thus emphasizing the potential detrimental effect that inherited variation in this developmental process can have on the tumorigenic potential of primordial germ cells.
This study is the first to our knowledge to implicate variation within genes involved in chromosomal segregation in cancer susceptibility. Karyotypes in TGCT are unique among cancers in that nearly all carry the same chromosomal aberration, a gain of 12p, most often in the form of an isochromosome, which is considered essential for tumor development [58] [59] [60] . Variation in these genes may lead to chromosomal instability and facilitate the development of aneuploidy. We also identified numerous potential regulatory SNPs, suggesting that newly identified associations might be mediated by plausible candidate genes within each locus, which warrant further fine-mapping and functional studies to elucidate the biological bases of the TGCT susceptibility regions. Studies of the genetic basis of TGCT continue to provide new insights into this unique disease with high heritability.
ONLINe MeThODS
Studies. Detailed characteristics of the study populations are given in both the Supplementary Note and in Supplementary Table 3 . Subjects used in the current study are all of European descent, and data from each study were collected and analyzed in accordance with local ethical permissions and informed consent. Three studies (STEED, FTCS and UPENN) were included in the discovery meta-analysis, and six studies contributed to replication by de novo genotyping (TestPAC, ATLAS, OUHRH and MDA) or in silico look-up in existing data (UKTCC and USC).
Genotyping and quality control. Genotype quality control metrics for the reported GWAS (UPENN and UKTCC) were previously described 18, 19 . Genotype quality control metrics for STEED, FTCS and USC are described in the Supplementary Note 61 . The OUHRH and MDA studies were genotyped using 5′ exonuclease assay (TaqMan) and the ABI Prism 7900HT sequence detection system, all according to the manufacturer's instructions, across several genotyping centers. Primers and probes were supplied directly by Applied Biosystems as Assays-By-Design. Technical validation was performed in HapMap samples (n = 270), with greater than 99% genotype concordance. TestPAC and ATLAS studies conducted genotyping using the iPLEX MassARRAY platform (Sequenom), following the manufacturer's protocol. Assays at all genotyping centers included at least four negative controls and 2-5% duplicates on each plate. A standard quality control protocol was implemented, requiring samples to have SNP call rates of >95% and no deviation from Hardy-Weinberg equilibrium in controls at P <0.00001, that <2% discordance between genotypes in duplicate had to be fulfilled and that cluster plots for SNPs that were close to failing any of the quality control criteria were re-examined centrally.
Statistical analysis. We analyzed two genome-wide scans from NCI (STEED and FTCS) as a combined data set using a logistic regression model for trend effect adjusted for age, study and additionally for one eigenvector (there was only one with P < 0.05) to account for population stratification in this population of European descent. From the top 500 SNPs by trend P values from the NCI scan, excluding previously reported ones, we selected 340 SNPs on the basis of the availability of surrogates (r 2 > 0.6) in the previous TGCT GWAS from the University of Pennsylvania. Because SNP content differs between the Illumina and Affymetrix platforms, we paired the best-correlated surrogate in the other array with each marker to perform a discovery meta-analysis (111 SNPs, direct match; 229 SNPs, surrogate match). From the discovery metaanalysis, we selected 17 of 40 SNPs with association P < 1 × 10 −4 for follow-up in the remaining studies. In silico follow-up was carried out in the USC and UKTCC scans, whereas additional genotyping was carried out in the TestPAC, ATLAS, OUHRH and MDA studies (Supplementary Table 3) . Not all markers were available for replication efforts at all sites (Supplementary Table 4) .
The meta-analysis was conducted using the suite of tools in GLU (Genotyping Library and Utilities) software, combining study-specific OR estimates using a fixed-effects model, which used the inverse-variance method to estimate combined ORs and their 95% CIs. To assess the existence of heterogeneity between studies, we used Cochran's Q statistic to calculate P values for heterogeneity.
Recombination hotspots were identified in the vicinity of the newly discovered TGCT-associated loci using SequenceLDhot 62 , a program that uses the approximate marginal likelihood method 63 and calculates likelihood-ratio statistics at a set of possible hotspots. We tested 5 unique sets of 100 control samples drawn from STEED. The PHASE v2.1 program was used to calculate background recombination rates 64, 65 , and LD heatmaps were visualized in r 2 using the snp.plotter program 66 .
The relative risk attributable to a set of SNPs (λ) was estimated using the following formula 67 where q i is the minor allele frequency (MAF) of SNP i and p i = 1− q i . SNPspecific risks for rare homozygotes, heterozygotes and common homozygotes are denoted by r 0i , r 1i and r 2i , respectively. The NCI controls (n = 1,140) were used to estimate MAFs, and OR estimates from SNP association analyses were used to estimate relative risks. This formula assumes that the effects of all SNPs in the set are multiplicative. The proportion of familial risk attributable to a set of SNPs was calculated as logλ/logλ 0 , where λ 0 is the familial relative risk estimated from TGCT epidemiological studies (λ 0 = 4 with an affected father, λ 0 = 8 with an affected brother) 68 .
Genomic annotation. Genomic annotation on high-LD surrogates (r 2 ≥ 0.8, 1000 Genomes Project CEU data) of five SNPs (rs17021463, rs12699477, rs4888262, rs9905704 and rs7221274) from the four TGCT susceptibility loci identified in the current study was conducted using the Encyclopedia of DNA Elements (ENCODE) tools HaploReg 69 and RegulomeDB 70 (Supplementary Table 5 ). rs12699477 did not have surrogates that met the requirement of r 2 ≥ 0.8; thus, we lowered the threshold to 0.7 for surrogates and then conducted annotation. All surrogates were queried in the RegulomeDB browser to cross-examine predicted regulatory DNA elements such as regions of DNase I hypersensitivity, binding sites of transcription factors and promoter regions that have been biochemically characterized to regulate transcription. Summaries of each SNP analysis by the RegulomeDB browser expressed in scores are shown in Supplementary Table 5 .
To predict potential regulatory SNPs, we assessed SNPs that met one of the following criteria: (i) conserved (GERP and/or Siphy); (ii) present in a promoter, enhancer or DNase I hypersensitivity region; or (iii) predicted to have a cis eQTL or having a RegulomeDB score of ≤3. Twenty-nine SNPs that passed one of these criteria also changed a transcription factor binding motif and are annotated further with the transcription factor motif of interest and the logarithm of odds (LOD) motif score for the specific SNP of interest (Supplementary Table 6 ). Two SNPs in 3′ UTRs were evaluated using SNP Function Prediction for changes in microRNA-binding sites and are included in Supplementary Table 6. 
